Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

16 trials with published results (9%)

Research Maturity

80 completed trials (46% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.6%

8 terminated out of 174 trials

Success Rate

90.9%

+4.4% vs benchmark

Late-Stage Pipeline

10%

18 trials in Phase 3/4

Results Transparency

20%

16 of 80 completed with results

Key Signals

16 with results91% success

Data Visualizations

Phase Distribution

93Total
Not Applicable (40)
Early P 1 (1)
P 1 (13)
P 2 (21)
P 3 (8)
P 4 (10)

Trial Status

Completed80
Unknown36
Recruiting26
Not Yet Recruiting15
Terminated8
Enrolling By Invitation4

Trial Success Rate

90.9%

Benchmark: 86.6%

Based on 80 completed trials

Clinical Trials (174)

Showing 20 of 20 trials
NCT06632444Phase 3Recruiting

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

NCT07754617Phase 2Not Yet Recruiting

Different Treatment Frequencies for Hepatic Fibrosis Due to Schistosomiasis: an RCT

NCT07730853Not ApplicableNot Yet Recruiting

Isocaloric Navy-Bean Substitution in Adults With MASLD

NCT00326482CompletedPrimary

Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy

NCT07102979Not ApplicableTerminatedPrimary

Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response

NCT06374875Phase 4Recruiting

Fibrosis Lessens After Metabolic Surgery

NCT07610837Phase 2RecruitingPrimary

Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis

NCT07069725Phase 1CompletedPrimary

The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.

NCT07716384Not Yet RecruitingPrimary

Wearable Patch Ultrasound Probe for Diagnosis of Liver Stiffness

NCT05935488CompletedPrimary

Early Liver Disease Breath Detection

NCT06750276Phase 2CompletedPrimary

A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.

NCT05699018Not ApplicableRecruiting

Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients

NCT06138821Not ApplicableRecruiting

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

NCT07658755Recruiting

Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme

NCT07629128Active Not Recruiting

Patients With Primary Biliary Cholangitis(PBC)

NCT06940375Completed

Incidence of Liver Disease-Related Outcomes in People With HIV

NCT07613827Not ApplicableEnrolling By Invitation

Interventional AI-Human Collaboration for Steatotic Liver Disease Screening

NCT07588854Recruiting

Correlation Of EUS-SWQ And Liver Fibrosis Pathology In Chronic Liver Disease

NCT07590284Not ApplicableNot Yet Recruiting

Sonazoid CEUS for Early HCC Surveillance

NCT01082419Not ApplicableCompletedPrimary

Acoustic Radiation Force Impulse Imaging (ARFI) : a New Technique to Assess Liver Elasticity

Scroll to load more

Research Network

Activity Timeline